PTC Therapeutics (PTCT) Posts Q4 Loss of 84c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks rally, crude prices fall
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
PTC Therapeutics (PTCT) Target Lifted to $81 at Wedbush
March 2, 2015 12:52 PM ESTWedbush analyst Heather Behanna reiterated an Outperform rating and boosted her price target on PTC Therapeutics (NASDAQ: PTCT) to $81.00 (from $68.00), noting the Translarna launch is off to a good start.
Behanna commented, "A combination of commercial launch in Germany and reimbursed expanded access... More
PTC Therapeutics (PTCT) PT Raised on BofA/Merrill Lynch on ex-US Translarna Sales
March 2, 2015 8:07 AM ESTBofA/Merrill Lynch analyst Tazeen Ahmad reiterated a Buy rating and boosted its price target on PTC Therapeutics (NASDAQ: PTCT) to $87.00 (from $60.00) following Q4 results and ex-US Translarna sales.
Ahmad notes that on the call PTC reported early ex-US launch metrics for its... More
